Engraftment syndrome (ES) is a toxicity of autologous stem cell transplantation that occurs unexpectedly and is occasionally fatal. This syndrome, manifested as fever, rash and pulmonary deterioration which becomes evident at marrow engraftment, has been described by several centers but as yet remains enigmatic. We describe this syndrome at a single institution and note that it has accompanied the transition from the use of autologous marrow rescue to peripheral blood stem cell rescue. In this study, the occurrence of ES is related to the mononuclear cell dose at reinfusion. We found, in agreement with other reports, that patients developing ES are predominantly women undergoing therapy for solid tumors who demonstrate neutrophil engraftment at a significantly greater rate than do those patients not expressing the syndrome. We did not note a significant relationship between growth factor use (G-CSF) or amphotericin B exposure and the syndrome, as has been previously reported. The progenitor cell populations obtained with autologous marow and peripheral blood stem cells are different. We hypothesize that the interaction of committed myeloid precursors from the stem cell product with the pulmonary vascular endothelium can be deleterious, especially under the influence of the inflammatory cytokines present at the time of engraftment. Bone Marrow Transplantation (2000) 25, 405-409. Keywords: engraftment syndrome; mononuclear cell; peripheral blood stem cells; progenitor cell Autologous marrow support has become increasingly commonplace in the management of human malignancy. The rescue from lethal marrow aplasia allows for the delivery of high doses of antineoplastic agents which, in theory, may effect improved tumor responsiveness and patient survival. become commonplace and has resulted in the recognition of previously undescribed toxicities.
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One such toxicity, termed the engraftment syndrome (ES), has been reported at several centers in the setting of both allogeneic and autologous bone marrow transplantation. [2] [3] [4] [5] [6] This syndrome, although variably defined, typically manifests as fever in the absence of infection, skin rash, and pulmonary injury which occur at the time of marrow engraftment. Additionally, weight gain, diarrhea and other organ dysfunction have also been included in some reports. [2] [3] [4] Given the breadth of definitions used to describe ES, the reported incidence of the syndrome is understandably variable and ranges from 9.8% 5 to nearly 60%. 3 The ES remains poorly understood at present but is felt to represent the complex interplay between cytokines present during early engraftment and cellular elements of the regenerating immune system and bone marrow. 2, 3, 5 At our institution we began to note the occurrence of ES upon changing from AM to PSC for hematopoietic rescue. This led us to hypothesize that some feature of the stem cell product contributed to the expression of ES. We were also interested in previous reports which correlated the use of amphotericin B with the occurrence of ES. 2 This is of particular interest due to the advent of improved fungal prophylaxis for bone marrow recipients. 7 Amphotericin B, which is often added empirically for persistent febrile neutropenia and has considerable toxicity, might be given with greater caution to those patients felt to be at risk for ES. The goal of our study was to characterize the patients who developed ES at our institution and to identify variables related to the development of ES, especially those potentially amenable to modification.
Methods
After approval from the hospital's institutional review board, we conducted a retrospective chart review of all patients over the age of 18 admitted for high-dose chemotherapy with AM or PSC support between August 1988 and July 1997. Complete records were available for 159 patients. The patients, 113 women and 46 men, had a median age of 41 years (range 19-66). Diagnoses included breast cancer (n = 99), Hodgkin's or non-Hodgkin's lymphoma (n = 27), acute myelogenous leukemia in remission (n = 5), multiple myeloma (n = 8), and other (n = 20). Preparative regimens were heterogeneous. Hematopoietic rescue was accomplished with AM (n = 66) or PSC (n = 84) or both AM and PSC (n = 9). The latter patients were included in the PSC group for the purpose of the analysis. Growth factor support, typically granulocyte colony-stimulating factor (G-CSF), was common. Thirty patients did not receive this or any other growth factor.
Supportive care included single rooms with HEPA filtered hoods. Antibiotic prophylaxis was routinely used in only the last 24 months and included oral ciprofloxacin and fluconazole. Herpes virus prophylaxis was utilized in all patients deemed at risk for recurrence by pre-transplant serum antibody titers and consisted of acyclovir at a dose of 200 mg i.v. three times daily. Treatment of febrile neutropenia included prompt initiation of a third generation cephalosporin as monotherapy or of an anti-pseudomonal penicillin and an aminoglycoside. Vancomycin and amphotericin B were added sequentially over the next 48-72 h for persistent fever or clinical deterioration unless specifically indicated by clinical findings or directed by a positive culture.
As per institutional protocol, red cell transfusion was performed to maintain the hematocrit over 25% and platelet transfusion given at a threshold of 20 000/ml. Cytomegalovirus (CMV)-negative products were utilized for those patients without measurable CMV neutralizing antibody titers. In the last 2 years, leukocyte-filtered blood products were often substituted for CMV-negative blood products.
Engraftment syndrome was defined as fever (Ͼ39°C), rash and evidence of pulmonary injury (either infiltrate or hypoxia) which could not be ascribed to aberrations of volume status, embolic events, or congestive heart failure. Importantly, these findings occurred in the absence of any positive microbial culture from blood, skin, throat, urine or stool. In order to qualify as an instance of ES, this constellation of findings should occur within 24 h of the appearance of neutrophils in the peripheral blood. The rationale for this is based on the finding that neutrophils and monocytes repopulate tissues before becoming detectable in the peripheral blood. 8 
Statistical analysis
Patients meeting the definition for ES were compared with the remainder of the group who did not develop the syndrome. Variables analyzed for association with ES included white blood cell count prior to stem cell harvest, baseline lung function parameters, CMV serologic status, total nucleated and mononuclear cells reinfused, growth factor usage, previous radiotherapy to neck and chest, amphotericin B use and time to early engraftment. Comparisons between groups were performed by Fisher's exact test (twotailed) for dichotomous variables and the Mann-Whitney U test for continuous variables. Statistical significance was assigned to P values Ͻ0.05 and all reported P values are two-sided.
Results
Eleven patients (6.9%) met the criteria for ES. Ten of the 11 patients were women undergoing high-dose chemotherapy for metastatic breast cancer (Table 1) . Whereas breast cancer accounted for 60% of all transplants in this series, 91% of ES patients carried this diagnosis (P = 0.02). Pre-transplant variables such as prior use of alkylating agents, prior irradiation to the chest or neck, CMV serologic status and pulmonary function parameters were analyzed for their putative association with ES. None of these variables proved useful as discriminators between the group of patients who developed ES and those who did not.
Due to the recognition that ES was occurring only after our center began using PSC as a means of hematopoietic rescue, we considered variables related to the storage and composition of the stem cell product. For the group as a whole, PSC was significantly associated with ES; no patient receiving AM developed ES (P Ͻ 0.004). Storage methods for PSC and AM were identical but the composition of the stem cell product obtained by these different methods was not. As seen in Table 1 , patients developing ES received significantly more mononuclear cells at stem cell reinfusion than those patients who did not develop the syndrome. There was no statistical difference between the two groups with respect to total nucleated cells collected. A trend towards higher white blood cell count prior to stem cell collection was noted in ES+ patients; however, this finding can be ascribed to the inclusion of AM patients in the ES− group. When only PSC patients were analyzed, there was no apparent association between the pre-pheresis white blood cell count and the development of ES.
The time from stem cell reinfusion to the first absolute neutrophil count (ANC) greater than zero was not different between the two groups (P Ͼ 0.5). In contrast, the time to early engraftment (ANC Ͼ 500) was significantly shorter in ES patients (see Table 2 ). This finding suggests that the rate of engraftment was more rapid in those patients who developed the syndrome. Indeed, these patients often demonstrated a two log increment in AN over 12-24 h; a representative case is shown in Figure 1 .
In the present study, no significant difference was noted between the two groups with regard to amphotericin exposure. There was a trend associating the use of growth factors with the development of ES. A larger sample size will be required to confirm this finding.
Overall, five patients required mechanical ventilation for 407 Table 1 Results of variable analysis Chi square test. AML = acute myelogenous leukemia; AM = autologous marrow; G-CSF = filgrastim; ES = engraftment syndrome; PSC = peripheral stem cell rescue; WBC = white blood cell count; ANC = absolute neutrophil count.
Table 2
Conditioning regimens for patients with engraftment syndrome pulmonary deterioration during the course of ES; two of these patients ultimately died as a direct consequence of the syndrome. The mortality rate for ES patients was 18% in this study, more than twice the rate for the group as a whole (8%).
Discussion
The incidence of ES found in this study is comparable to other published reports utilizing a similar definition of the syndrome. 5 As previously mentioned, the majority of the patients with ES were women undergoing therapy for breast cancer. The finding of gender predominance has been noted previously 4, 6 but this finding has largely been ascribable to the predominance of breast cancer transplants in the reported series. Ravoet et al, 5 however, reported on a series of 61 patients of which 45 had hematologic neoplasms; in this series, the majority of the cases of ES were also in women.
Given the predominance of women with breast cancer in the reported series of ES, it is reasonable to suggest a possible contribution of pretransplant chemotherapy to the occurrence of the syndrome. Alkylating agents, commonly employed in the management of cancer, are known to produce pulmonary injury. 9 Unfortunately, assessing the impact of alkylator therapy in this population of patients is quite difficult due to nearly ubiquitous use of these agents in the management of breast cancer and lymphomas. In fact, nearly 89% of patients in the present series had received some form of alkylator therapy prior to high-dose chemotherapy and transplant. Alkylating agents are the fundamental component of most high-dose regimens as well; some of these, namely busulfan 9 and cyclophosphamide [10] [11] [12] are known to produce severe and even fatal pulmonary toxicity. The variability of the conditioning regimens utilized and the small number of patients with ES preclude any definitive statement regarding the contribution of high-dose alkylator therapy to ES; however, a tabulation of the conditioning regimens for the affected patients is given in Table 2 . Despite the observation that the regimen containing carboplatin/etoposide/cyclophosphamide was most commonly associated with ES, this finding was not significant. To date, no published report clearly implicates the use of alkylator therapy or any particular conditioning regimen as critical for the development of ES. An important observation from this study is that all patients who developed ES received PSC as hematopoietic rescue. With the exception of the large series reported by Lee et al, 3 which utilized a broad definition of ES, all other reported cases of ES have involved the use of PSC (either alone or with AM). [4] [5] [6] Although the biologic basis for this finding is unclear, hematopoietic progenitor subpopulations obtained from marrow harvest or peripheral blood are quite different. With the latter method, a predominance of CD34 + /CD33 + cells are collected and are believed to represent committed myeloid precursor cells. 13 We also investigated the role of cell dosage at reinfusion and found that patients developing ES received significantly more mononuclear cells when compared with non-ES patients. Although this finding is in contrast to a previous report, 6 it is compatible with the intriguing finding of Ravoet et al 5 who correlated the development of ES with the dose of CD34
+ cells delivered at reinfusion (see Table  3 ). Evaluation of CD34 + yield has begun only recently at our institution and this finding cannot be duplicated at this time due to small numbers of patients with complete information.
Previous reports have described the association of ES with early and steep neutrophil recovery. 4, 5 Similarly in our series, patients developing ES achieved ANC Ͼ 500 significantly more rapidly than non-ES patients. These findings, in aggregate, support the contention that the neutrophil is in some way contributing to the expression of the syndrome. Neutrophil-mediated endothelial injury is welldescribed 14, 15 and is postulated to be a component of the acute respiratory distress syndrome. 16 Although our findings do not support the conclusion that amphotericin B contributes to ES, this finding is in contrast to that of a large series reported by Cahill et al 2 who found a significant association with engraftment toxicity and this antifungal. This finding is of great importance given the routine implementation of this agent for the management of persistent febrile neutropenia despite antibacterial therapy. Amphotericin can have deleterious effects on the pulmonary endothelium 17 and severe pulmonary toxicities have been described with its use. 18, 19 Lethal pulmonary reactions, bearing some resemblance to ES, have been described when amphotericin is used concurrently with granulocyte transfusions. 20 Given the small number of patients with ES, the absence of demonstrable contribution from amphotericin B in this study should be viewed with some caution.
Administration of hematopoietic growth factors has been shown to hasten neutrophil recovery after bone marrow reinfusion. 21 G-CSF is routinely administered during rescue with AM or PSC and has few serious side effects. Lee et al, 3 however, described a significant association of G-CSF use with the development of ES. Other series have noted lesser 5 or no association 6 with cytokine administration. G-CSF is known to promote myeloid progenitor expansion and differentiation. 22 Moreover, this cytokine leads to priming of the granulocyte oxidative burst 23, 24 thus magnifying the response of these cells at the site of tissue injury. Given the relationship between the development of ES with neutrophil recovery, one could reasonably postulate a role for G-CSF in the pathogenesis of the syndrome. Anecdotally, Ravoet et al 5 reported a single patient who developed ES in association with G-CSF and that the syndrome did not recur during a second transplant not supported with this cytokine. 5 Despite the trend demonstrated in this study, more patients will be required to definitively associate cytokine use with ES.
The pathogenesis of ES remains obscure but some important features have emerged. We hypothesize that some patients undergoing high-dose chemotherapy develop pulmonary injury during treatment. In the absence of inflammatory cells (due to myeloablation), this injury remains occult. Reinfusion of high numbers of committed myeloid precursors (CD34 + /CD33 + ) and subsequent G-CSF use leads to rapid neutrophil recovery. These neutrophils, under the effects of exogenous G-CSF and endogenous inflammatory cytokines present at engraftment, [25] [26] [27] appropriately localize to the sites of pulmonary injury and result in the clinical syndrome. Validation of this hypothesis rests with determining the nature of the pulmonary injury and evaluating the inflammatory cytokine profile at the tissue level (lung). These studies are currently underway.
